ISHL International Symposium on Hodgkin Lymphoma Program at a Glance

Saturday (03.10.2026) Sunday (04.10.2026) Monday (05.10.2026)
 
Großer Saal


HL in Children and Adolescents

  • J. Flerlage
  • C. Mauz-Körholz

  1. Treatment Evolution in Pediatric Hodgkin Lymphoma: From Research to Real-World Impact

    • M. Mascarin

  2. Precision Medicine in Pediatric HL / Harmonized Pediatric HL Protocol in South Africa

    • J. Geel

  3. Abstract T071: The Genomic Landscape of Pediatric High-Risk Hodgkin Lymphoma: A Liquid Biopsy Study of COG AHOD1331

    • L. Marks

  4. Abstract T072: Body-Size Normalisation of Metabolic Tumour Volume in Paediatric Hodgkin Lymphoma: Does MTV/BSA Improve Prognostic Stratification and Reclassify Smaller Children?

    • C. Gowdy
Ratsstube


🔒 Closed Workshop on Grassroot Initiative in Classic Hodgkin Lymphoma
(Separate registration required)

  • R. Advani
  • P. Borchmann
  • P. Oyiro
Großer Saal


Special Cases & Situations

  • P. Bröckelmann
  • J. Zijlstra

  1. HL in Pregnancy

    • A. Robertz

  2. Critical Organ Failure at Presentation

    • H. Tharmaseelan

  3. Anti-PD1 Tx in Pre-Existing Autoimmune Disease

    • Y. Jauw

  4. Workshop Report “Grassroot Initiative in Classic Hodgkin Lymphoma”

    • R. Advani
    • P. Oyiro
Großer Saal


EHA-LYG/GHSG Joint Session: EHA Clinical Practice Guidelines in Lymphoid Malignancies - From Recommendations to Patient Care

  • I. Aurer
  • B. von Tresckow

  1. Large B-cell lymphomas

    • S. Leppä

  2. Mantle cell lymphoma

    • I. Aurer

  3. Follicular lymphoma

    • K. Linton

  4. HIV-related lymphomas

    • M. Hentrich

  5. Peripheral T-cell lymphoma

    • F. d'Amore

  6. New Therapeutic Concepts and Horizons in Lymphoma

    • C. Diefenbach


Joint-symposiums, Seminars and Workshops (⏲ parallel sessions)

  1. 🔒 Workshop: Workshop on ctDNA in HL
    (Separate registration required)

    • S. Alig
    • S. Borchmann
    • M. Pirosa
    • C. Steidl

  2. 🔒 Workshop: Individualization of Radiation Therapy for Hodgkin Lymphoma
    (Separate registration required)

    • H. Eich
    • J. Yahalom
Coffee Break
Coffee Break
Großer Saal


New concepts for the treatment of B-cell lymphomas

by MSD Sharp & Dohme GmbH
  • B. von Tresckow

  1. DLBCL – The current and future role of ADCs in the context of T-cell engaging therapies

    • B. Chapuy

  2. cHL – Treatment strategies for PD-1 inhibition in the relapsed / refractory setting

    • B. von Tresckow
Großer Saal


NLPHL

  • R. Hoppe
  • W. Klapper

  1. Clinical Implications of Growth Patterns

    • D. Eichenauer

  2. Treatment Strategies

    • J. Flerlage

  3. Abstract T101: Single-Nuclei and Spatial Transcriptomic Analysis of Nodular Lymphocyte- Predominant Hodgkin Lymphoma (NLPHL)

    • H. Dong

  4. Abstract T102: Malignant LP cells build a stroma-poor, avascular niche that concentrates IDO1+ macrophages and excludes regulatory T cells in NLPHL and THRLBCL

    • I. Kalashnikov
 
Coffee Break
Coffee Break
Großer Saal


Translating ctDNA into clinical routine

  • S. Borchmann
  • M. Shipp

  1. Circulating Tumor DNA: New insights from the SWOG S1826 study.

    • M. Shipp

  2. Circulating Tumor DNA Analysis for Classification and MRD Assessment – Experience of the German Hodgkin Study Group

    • S. Borchmann

  3. Workshop Report

    • C. Steidl

  4. Abstract T048: A Reproducible Mutation- versus Copy-Number-Enriched Genomic Axis Underlies Molecular Subtypes of Classic Hodgkin Lymphoma

    • C. Lange
Großer Saal


Relapsed & Refractory HL

  • C. Moskowitz
  • A. Sureda

  1. 2L Treatment of HL in Era of Novel Agents

    • A. Moskowitz

  2. Revisiting the Role of Stem Cell Transplantation in rrHL

    • B. von Tresckow

  3. Unmet Needs and Novel Treatment Approaches in >3L

    • M. Hutchings

  4. Abstract T106: Phase 1 PRIMAVERA Study of the PRMT5 Inhibitor AZD3470 in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma

    • P. Zinzani

  5. Abstract T107: Treatment patterns and survival outcomes of patients relapsing after frontline Nivolumab-AVD in advanced stage classical Hodgkin lymphoma (cHL)

    • H. Shah

  6. Abstract T108: Primary Analysis of the GHSG Pembro-CORE Trial: PET-Adapted PD-1-Based Salvage Therapy Omitting High-Dose Chemotherapy in First-Relapsed Hodgkin Lymphoma

    • H. Tharmaseelan
Coffee Break
Großer Saal


Moving Targets: Rethinking Cellular Therapy Delivery in Aggressive B-Cell Lymphomas

by Miltenyi Biomedicine

  1. Opening and Framing

    • B. von Tresckow

  2. R/R DLBCL Treatment Landscape

    • B. von Tresckow

  3. Difficult-to-Treat Patients in R/R DLBCL

    • I. Aurer

  4. CAR-T Delivery and Treatment Timing: Clinical Challenges and Opportunities

    • B. von Tresckow

  5. Future Directions in Cellular Therapy

    • A. Sureda

  6. Panel Discussion and Q&A
Lunch Break
Großer Saal


Biology & Pathology

  • W. Klapper
  • C. Steidl

  1. The Biology of HRS Cells

    • R. Küppers

  2. Novel Insights Into the Microenvironment of Hodgkin Lymphoma

    • T. Aoki

  3. Abstract T046: Functional characterization of STAT6 mutations as oncogenic drivers in classical Hodgkin lymphoma (cHL)

    • L. Tasselli

  4. Abstract T047: Artificial intelligence predicts EBV status and reveals prognostic morphology phenotypes in advanced-stage classic Hodgkin lymphoma

    • H. Tharmaseelan
Großer Saal


Best of ISHL14

  1. Best of ISHL14

    • R. Advani

  2. Farewell

    • P. Borchmann
Lunch Break
Meeting adjourns
Großer Saal


Early Stages

  • C. Diefenbach
  • H. Eich

  1. Personalized RTx: Focus on RTx Techniques and Late Effect Prediction Models

    • D. Cutter

  2. Just PD1-Inhibition? Early Insights from the GHSG INDIE Trial

    • P. Bröckelmann

  3. Debate: Should Novel Agents Be Integrated Into the Frontline Treatment of Early Stage Low Risk HL Patients?

    • G. Collins
    • C. Diefenbach

  4. Abstract T082: Radiation-free initial treatment of early-stage favorable classic Hodgkin Lymphoma (RAFTING) trial: three-year follow-up

    • J. Zaucha

  5. Abstract T083: Integrating E-HIPI and Interim PET to Refine Risk Stratification in Early-Stage Classic Hodgkin Lymphoma

    • A. Cellini
Coffee Break
Großer Saal


From Evidence to Experience: How Long-Term and Real-World Data for ADCETRIS® (brentuximab vedotin) May Inform Frontline Practice in Advanced Hodgkin Lymphoma

by Takeda Oncology
  • B. von Tresckow

  1. Welcome and Introductions

    • B. von Tresckow

  2. Enhancing Frontline Management in Advanced HL with BrECADD

    • O. Baiocchi

  3. Advancing HL Control and Fertility Preservation with BrECADD

    • E. Dann

  4. Optimizing Care in High-Risk HL with A+AVD

    • C. Burton

  5. Engage with the Experts (Q&A)

  6. Meeting close

    • B. von Tresckow
Coffee Break
Großer Saal


Raising the bar in cHL: From frontline treatment to long-term impact

by Bristol Myers Squibb
  • P. Borchmann
  • S. Castellino
  • A. Herrera

  1. Welcome and introduction

    • P. Borchmann

  2. The current treatment landscape and challenges in cHL

    • P. Borchmann

  3. Current and emerging frontline treatment strategies in adult and elderly patients with cHL

    • A. Herrera

  4. N-AVD vs BrECADD in advanced stage frontline cHL

    • P. Borchmann
    • S. Castellino
    • A. Herrera

  5. Current and emerging frontline and R/R treatment strategies in pediatric patients with cHL

    • S. Castellino

  6. Treatment of frontline cHL in a pediatric patient

    • S. Castellino

  7. Panel Q&A session and discussion

    • P. Borchmann

  8. Summary and close

    • P. Borchmann
Coffee Break
Großer Saal


Living Beyond Lymphoma

  • M. Büttner
  • A. Fosså

  1. Evaluating Late Effects of Contemporary Treatments - Competing Risks & Novel Approaches

    • C. Dietrich

  2. Uncertainties with Anti-PD1 & irAE in the First-Line Setting

    • P. Bröckelmann

  3. In Conversation with GHSG Patient Representatives: Building a Bridge Between Cancer Treatment and Everyday Life – Challenges After Lymphoma

    • K. Behringer
    • G. patient representatives

  4. Abstract T092: Patients with a history of Hodgkin lymphoma have lower quality of life than matched comparators regardless of time elapsed since diagnosis

    • P. Kamper

  5. Abstract T093: The MyHodgkin MyHealth App: patient-derived data for tracking Hodgkin Lymphoma survivorship

    • N. Wong Doo
Coffee Break
Großer Saal


Opening Ceremony with Keynote Lecture & Awards

  1. Welcome Address

    • P. Borchmann

  2. Karl-Musshoff Awards & Poster Awards,

    • P. Borchmann
    • P. Bröckelmann
    • D. Eichenauer
    • J. Ferdinandus

  3. Keynote Lecture: Changing treatment paradigms in B cell Lymphoma

    • G. Salles
Großer Saal


Advanced Stages

  • P. Armand
  • G. Collins
  • M. Hertzberg

  1. Unmet Needs and Future Perspectives with BrECADD: Improving Outcomes of HD21

    • J. Ferdinandus

  2. Unmet Needs and Future Perspectives with Nivo-AVD: Unanswered Questions from SWOG S1826

    • A. Herrera

  3. Abstract T001: CHOP/miniCHOP And Tislelizumab in EldeRly patients with classical Hodgkin Lymphoma (cHL). A report of the phase II CATER-HL trial (HD12) from the Australasian Lymphoma and Leukaemia Group (ALLG)

    • T. Cochrane

  4. Abstract T002: Simplified Geriatric Assessment (sGA) in Older Patients With Classical Hodgkin Lymphoma (cHL): The Prospective ELDHL Project of the Fondazione Italiana Linfomi (FIL)

    • V. Zilioli

  5. Abstract T003: Durable Remissions and Late Immune-Related Toxicities After Frontline Pembrolizumab + AVD in Classic Hodgkin Lymphoma

    • R. Lynch
Foyer (Ground Floor)


Poster Session & Welcome Reception

  1. Project Pitch & Collaboration Plaza

    • S. Ansell
    • A. Evens
    • J. Ferdinandus
    • J. Friedberg
    • A. Herrera
    • W. Plattel

  2. Early Stages

    • C. Baues
    • C. Diefenbach

  3. HL in Children & Adolescents

    • C. Mauz-Körholz
    • J. Yahalom

  4. Biology & Pathology

    • W. Klapper
    • S. Leppä

  5. Living Beyond Lymphoma

    • K. Behringer
    • J. Radford

  6. Advanced Stages

    • B. von Tresckow
    • J. Zijlstra

  7. Resource Constrained Settings

    • O. Baiocchi
    • L. Specht

  8. NLPHL

    • D. Eichenauer

  9. Relapsed & Refractory HL

    • H. Ghesquieres
    • P. Zinzani
 
 
  •   Main Program
  •   Satellite Symposium
  •   Scientific Session
  •   Joint Symposium/Seminar/Workshop